TY - JOUR
T1 - Structure-Activity Relationship Insight of Naturally Occurring Bioac-tive Molecules and Their Derivatives Against Non-Small Cell Lung Cancer
T2 - A Comprehensive Review
AU - Das, Subham
AU - Roy, Shubham
AU - Rahaman, Seikh Batin
AU - Akbar, Saleem
AU - Ahmed, Bahar
AU - Halder, Debojyoti
AU - Ramachandran, Anu Kunnath
AU - Joseph, Alex
N1 - Funding Information:
Subham Das acknowledges the Indian Council of Medical Research (ICMR) for assisting in the Senior Research Fellowship (SRF) [Fellowship ID 2021-13515]. Another author Saleem Akbar acknowledges the Indian Council of Medical Research (ICMR) for their support in the Senior Research Fellowship (S-RF) [Letter No. 3/2/2/38/2020-NCD-III].
Publisher Copyright:
© 2022 Bentham Science Publishers.
PY - 2022/12
Y1 - 2022/12
N2 - Background: Non-small cell lung cancer (NSCLC) is a deadly disease that affects mil-lions globally and its treatment includes surgery, chemotherapy, and radiotherapy. Chemotherapy and radiotherapy have many disadvantages, which include potential harmful side effects. Due to the wide-spread use of drugs in lung cancer, drug treatment becomes challenging due to multidrug resistance and adverse reactions. According to the recent findings, natural products (NPs) and their derivatives are being used to inhibit and suppress cancer cells. Objective: Our objective is to highlight the importance of phytochemicals for treating NSCLC by fo-cusing on the structural features essential for the desired activity with fewer side effects compared to synthetic molecules. Methods: This review incorporated data from the most recent literature, including in vitro, in vivo, nanoformulation-based recent advancements, and clinical trials, as well as the structure-activity relationship (SAR), described for a variety of possible natural bioactive molecules in the treatment of NS-CLC. Results: The analysis of data from recent in vitro, in vivo studies and ongoing clinical trials are high-lighted. The SAR studies of potential NPs signify the presence of several common structural features that can be used to guide future drug design and development. Conclusion: The role of NPs in the battle against NSCLC can be effective, as evidenced by their structural diversity and affinity toward various molecular targets. The main purpose of the review is to gather information about NPs used in the treatment of NSCLC.
AB - Background: Non-small cell lung cancer (NSCLC) is a deadly disease that affects mil-lions globally and its treatment includes surgery, chemotherapy, and radiotherapy. Chemotherapy and radiotherapy have many disadvantages, which include potential harmful side effects. Due to the wide-spread use of drugs in lung cancer, drug treatment becomes challenging due to multidrug resistance and adverse reactions. According to the recent findings, natural products (NPs) and their derivatives are being used to inhibit and suppress cancer cells. Objective: Our objective is to highlight the importance of phytochemicals for treating NSCLC by fo-cusing on the structural features essential for the desired activity with fewer side effects compared to synthetic molecules. Methods: This review incorporated data from the most recent literature, including in vitro, in vivo, nanoformulation-based recent advancements, and clinical trials, as well as the structure-activity relationship (SAR), described for a variety of possible natural bioactive molecules in the treatment of NS-CLC. Results: The analysis of data from recent in vitro, in vivo studies and ongoing clinical trials are high-lighted. The SAR studies of potential NPs signify the presence of several common structural features that can be used to guide future drug design and development. Conclusion: The role of NPs in the battle against NSCLC can be effective, as evidenced by their structural diversity and affinity toward various molecular targets. The main purpose of the review is to gather information about NPs used in the treatment of NSCLC.
UR - http://www.scopus.com/inward/record.url?scp=85137031742&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85137031742&partnerID=8YFLogxK
U2 - 10.2174/0929867329666220509112423
DO - 10.2174/0929867329666220509112423
M3 - Review article
C2 - 35579166
AN - SCOPUS:85137031742
SN - 0929-8673
VL - 29
SP - 6030
EP - 6062
JO - Current Medicinal Chemistry
JF - Current Medicinal Chemistry
IS - 39
ER -